Prescribing trends for dabigatran etexilate in primary care

Irish Medical Journal

Volumn 105, Issue 5, 2012, Pages

  McCullagh, L ^a   Barry, M ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; DABIGATRAN ETEXILATE;

ARTICLE; CHRONIC DRUG ADMINISTRATION; COHORT ANALYSIS; DISEASE CONTROL; DRUG APPROVAL; DRUG COST; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCRIPTION; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; STROKE; TREATMENT DURATION; TREND STUDY;

EID: 84863874413     PISSN: 03323102     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Boehringer Ingelheim LTD. Pradaxa (dabigatran etexilate) 110mg Hard Capsules. IPHA Medicines Compendium. 15 Feb 2011. Available from URL: http://www.medicines.ie. [Accessed 2011 July 04].
2. McCullagh L, Tilson L, Walsh C, Barry M. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting. Pharmacoeconomics 2009;27:829.
3. Stewart S, Hart C, Hole D, McMurray J. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001;86:516-521.
4. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation. Eur Heart J 2010;31:2369-2429.
5. Lip GH. Does atrial fibrillation confer a hypercoagulable state? Lancet 1995;346:1313-1314.
6. Hannon N, Sheehan O, Kelly L, Marnane M, Merwick A, Moore A, Kyne L, Duggan J, Moroney J, McCormack PM, Daly L, Fitz-Simon N, Harris D, Horgan G, Williams EB, Furie KL, Kelly PJ. Stroke associated with atrial fibrillation - Incidence and early outcomes in the North Dublin Population Stroke Study. Cerebrovascular Dis 2010;29:43.
7. Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, Lip GY, Manning WJ. Antithrombotic therapy in atrial fibrillation. Chest 2008;133:546S-592S.
8. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann of Intern Med 2007;146:857.
9. Connolly S, Ezekowitz M, Yusuf S, Eikelboom J, Oldgren J. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361.
10. Connolly S, Ezekowitz D, Yusuf S, Reilly P, Wallentin L. for the Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in RE-LY. N Engl J Med 2010;363:1875-1876.
11. Connolly S, Ezekowitz M. Correspondance. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009;361:2674.
12. RELY-ABLE. Long-term multi-centre extension of dabigatran treatment in patients with atrial fibrillation who completed RE-LY trial. Available at www.clinicaltrials.gov [Accessed 2011 July 04].
13. Garcia D. Novel anticoagulants and the future of anticoagulation. Thromb Res 2009;123.
14. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment. Chest 2008;133(6 suppl):257S-298S.
15. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ. RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Eng J Med 2009;361:2342-2352.
16. Melnikova I. The anticoagulant market. Nat Rev Drug Discov 2009;8:353-354.